SCHEMBL1491400

SCHEMBL1491400

O=C(CCCCCCC(=O)N1CCc2c([nH]c3ccccc23)C1C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)NO

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.48
▸ HDAC6 Q9UBN7 2/20 0.48
▸ LMNA P02545 10/20 0.42
▸ TP53 P04637 3/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MMP2 P08253 2/20 0.40
▸ MMP9 P14780 2/20 0.40
▸ ANPEP P15144 2/20 0.40
▸ LTA4H P09960 1/20 0.40
▸ LAP3 P28838 1/20 0.40
▸ NPEPPS P55786 1/20 0.40
▸ ERAP2 Q6P179 1/20 0.40
▸ ERAP1 Q9NZ08 1/20 0.40
▸ ABCB1 P08183 1/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491403 1.00 HDAC1 (0.48) HDAC1HDAC6LMNATP53MEN1
SCHEMBL14930036 0.91 HDAC1 (0.51) HDAC1HDAC6LMNATP53MEN1
SCHEMBL1491340 0.90 TP53 (0.46) HDAC1LMNATP53MAPTABCG2
SCHEMBL1491342 0.90 TP53 (0.46) HDAC1LMNATP53MAPTABCG2
SCHEMBL1491428 0.89 HDAC1 (0.54) HDAC1HDAC6LMNATP53MEN1
SCHEMBL1491430 0.89 HDAC1 (0.54) HDAC1HDAC6LMNATP53MEN1
SCHEMBL1493521 0.88 HDAC1 (0.47) HDAC1HDAC6LMNATP53MEN1
SCHEMBL1493519 0.88 HDAC1 (0.47) HDAC1HDAC6LMNATP53MEN1
SCHEMBL1493520 0.88 HDAC1 (0.47) HDAC1HDAC6LMNATP53MEN1
SCHEMBL8252712 0.88 HDAC1 (0.51) HDAC1HDAC6LMNATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 — — US disclosed
US-7939666-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-05-10 — — US disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 — — EP disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 — — US disclosed
EP-1879895-A1 ENZYME INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-23 — — EP disclosed
WO-2006117549-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116318-A1 Enzyme Inhibitors HDAC1, HDAC11, HDAC7 HDAC1 1/4885HDAC6 11/4885LMNA 2584/4885
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 HDAC1 9/4885HDAC6 1058/4885LMNA 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback